KMT2A and leukemia: The identification of the adenosine analog, 2-Cl-ATP as a selective inhibitor of KMT2A-r leukemia cell lines, is in line with previous studies highlighting the sensitivity of KMT2A-r leukemia to nucleoside analogs (17, 18) and supports the validity of our screening approach to identify KMT2A-r selective candidate drugs.